human
monoclon
antibodi
humab
prepar
patient
viral
infect
could
provid
inform
human
epitop
import
develop
vaccin
well
potenti
therapeut
applic
fusion
peripher
blood
mononuclear
cell
total
five
influenzavaccin
volunt
newli
develop
murinehuman
chimera
fusion
partner
cell
name
spymeg
obtain
hybridoma
clone
stabli
produc
antiinfluenza
viru
antibodi
one
influenza
four
influenza
five
influenza
b
surprisingli
humab
show
broad
reactiv
within
subtyp
four
two
two
b
show
broad
neutral
abil
importantli
epitop
map
reveal
two
broad
neutral
antibodi
deriv
differ
donor
recogn
epitop
locat
underneath
receptorbind
site
hemagglutinin
globular
region
highli
conserv
among
strain
technolog
monoclon
antibodi
mab
prepar
import
provid
materi
character
uniqu
epitop
conform
structur
well
develop
rapid
diagnost
kit
acut
infect
could
effect
prevent
passiv
immun
strategi
evidenc
success
treatment
healthcar
worker
infect
sever
acut
respiratori
syndrom
sar
coronaviru
transfus
convalesc
phase
plasma
obtain
sar
patient
success
protect
viral
infect
mous
model
sarscoronaviru
infect
human
mab
humab
obtain
patient
memori
cell
repertoir
also
studi
spanish
flu
evalu
effect
transfus
influenzaconvalesc
blood
product
may
offer
insight
regard
potenti
treatment
infect
furthermor
report
avian
flu
patient
recov
follow
treatment
convalesc
plasma
donor
recent
sever
trial
use
mab
neutral
activ
prevent
acut
sever
symptom
influenza
viru
infect
includ
protect
properti
mab
direct
stem
region
hemagglutinin
ha
influenza
viru
demonstr
mice
base
data
prepar
humab
virus
caus
sever
acut
diseas
potenti
therapeut
applic
becom
great
import
sever
factor
affect
develop
humab
sourc
immun
cell
humanderiv
memori
b
plasma
cell
murin
cell
procedur
immort
immun
cell
fusion
appropri
partner
cell
line
eb
virusbas
transform
molecular
clone
immunoglobulin
gene
use
phage
display
human
murin
mab
recent
rapid
clone
method
highaffin
humab
influenza
viru
establish
use
singlecel
revers
transcriptasepolymeras
chain
reaction
immunoglobulin
variabl
region
singlesort
plasma
cell
secret
influenzaspecif
igg
deriv
influenzavaccin
healthi
volunt
use
studi
employ
novel
approach
develop
humab
influenza
virus
use
newli
prepar
cell
line
name
spymeg
gener
fusion
myeloma
cell
murin
origin
human
megakaryoblast
leukemia
cell
humab
show
broad
neutral
activ
human
influenza
b
virus
volunt
total
five
healthi
volunt
receiv
influenza
vaccin
select
yearold
male
b
yearold
femal
c
yearold
male
yearold
male
e
yearold
femal
ten
millilit
blood
obtain
individu
volunt
pbmc
prepar
centrifug
ficol
pack
plu
ge
healthcar
uppsala
sweden
min
vaccin
cell
fusion
pbmc
fuse
spymeg
cell
ratio
polyethylen
glycol
fuse
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fc
micropl
day
presenc
hat
first
screen
cultur
medium
antibodi
specif
influenza
virus
perform
enzymelink
immunosorb
assay
elisa
describ
specif
antibodyposit
well
next
subject
cell
clone
limit
dilut
second
screen
also
perform
elisa
elisa
micropl
coat
viral
antigen
react
cultur
medium
fuse
cell
min
room
temperatur
follow
peroxidaseconjug
rabbit
antihuman
igg
medic
biolog
laboratori
aichi
japan
immunofluoresc
assay
monolay
mdck
cell
chamber
slide
mockinfect
infect
influenza
b
virus
h
incub
infect
cell
fix
ethanol
react
cultur
medium
individu
hybridoma
cell
clone
control
antibodi
use
sever
murin
mab
ie
nucleoprotein
np
influenza
viru
ha
ha
okuno
unpublish
np
influenza
b
viru
ha
influenza
b
viru
cell
react
fluorescein
isothiocyan
fitc
conjug
rabbit
antihuman
antimous
antibodi
jackson
immunoresearch
cambridgeshir
uk
western
blot
purifi
ha
vaccin
antigen
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
sampl
buffer
subject
electrophoresi
polyacrylamid
gel
protein
gel
blot
onto
polyvinyliden
difluorid
membran
incub
cultur
medium
individu
hybridoma
clone
incub
peroxidaseconjug
goat
antihuman
igg
h
l
antibodi
jackson
immunoresearch
peroxidas
reaction
membran
visual
use
ecl
western
blot
detect
system
ge
healthcar
uppsala
sweden
peroxidas
antiperoxidas
pap
stain
pap
stain
carri
describ
previous
briefli
mdck
cell
infect
multipl
infect
influenza
viru
cultur
h
fcsfree
dmem
infect
cell
fix
ethanol
react
cultur
medium
individu
hybridoma
cell
clone
control
use
sever
murin
mab
mention
cell
incub
rabbit
antihuman
antimous
igg
antibodi
cappel
goat
antirabbit
igg
antibodi
cappel
final
pap
complex
cappel
hemagglutinininhibit
hi
test
hi
test
carri
describ
previous
cultur
medium
individu
hybridoma
clone
treat
receptor
destroy
enzym
rde
result
express
reciproc
highest
dilut
cultur
medium
show
inhibit
viru
neutral
vn
test
vn
test
carri
describ
previous
briefli
cultur
media
individu
hybridoma
clone
treat
rde
dilut
serumfre
medium
dilut
cultur
medium
individu
hybridoma
clone
mix
ffu
influenza
viru
appli
mdck
cell
micropl
cultur
h
cell
fix
ethanol
stain
pap
data
express
percentag
infect
sequenc
analysi
humab
variabl
region
total
rna
extract
hybridoma
cell
revers
transcript
rt
perform
min
use
human
iggh
rtprimer
iggl
rtprimer
kappa
chain
also
use
dt
primer
lambda
chain
next
perform
race
pcr
smart
tm
race
cdna
amplif
kit
clontech
laboratori
mountain
view
ca
use
human
iggh
raceprim
aaggtg
human
iggl
kappa
raceprim
gt
human
iggl
lambda
raceprim
revers
primer
univers
primer
mix
forward
primer
clone
pcr
product
clone
plasmid
takara
bio
kyoto
japan
sequenc
analysi
perform
sequenc
perkin
elmer
waltham
use
primer
rv
primer
bigdy
termin
cycl
sequenc
kit
perkin
elmer
epitop
map
total
set
peptid
overlap
amino
acid
span
amino
acid
aa
residu
region
jpt
peptid
technolog
gmbh
berlin
germani
subject
bind
activ
assay
use
peptid
microarray
humab
obtain
ethic
human
materi
collect
use
protocol
approv
institut
review
board
research
institut
microbi
diseas
osaka
univers
ten
millilit
blood
five
volunt
obtain
variou
time
point
influenza
vaccin
fusion
spymeg
cell
experi
total
well
posit
influenza
virusspecif
humab
first
screen
howev
subsequ
cell
clone
expans
largescal
cultur
hybridoma
cell
clone
lost
abil
produc
humab
eventu
hybridoma
clone
found
stabli
produc
specif
humab
least
month
tabl
efficaci
detect
specif
antibodyproduc
well
higher
pbmc
deriv
vaccin
week
postvaccin
next
determin
influenza
viru
type
recogn
individu
humab
first
immunofluoresc
analysi
carri
result
follow
recogn
recogn
recogn
b
virus
repres
result
influenza
viru
influenza
b
viru
shown
fig
control
antibodi
use
sever
antiinfluenza
ha
np
murin
mab
stain
pattern
infect
mdck
cell
obtain
humab
similar
obtain
antiha
antinp
murin
mab
pap
stain
elisa
humab
gave
result
tabl
five
mab
b
show
distinct
band
ha
protein
western
blot
mab
show
littl
reactiv
viral
protein
includ
ha
method
indic
recognit
conform
epitop
fig
control
antibodi
use
dilut
donor
bderiv
plasma
antib
humab
obtain
studi
next
examin
crossreact
sever
vaccin
strain
influenza
viru
subtyp
pap
stain
vn
test
humab
except
weakli
react
show
broad
reactiv
strain
within
subtyp
pap
stain
tabl
next
humab
examin
broad
neutral
activ
sever
b
viru
strain
fig
result
vn
test
similar
pap
strain
show
strong
neutral
activ
vaccin
strain
isol
respect
show
mild
neutral
activ
b
victoriagroup
yamagatagroup
strain
isol
crossreact
humab
among
data
shown
andor
b
virus
tabl
interestingli
littl
hi
activ
detect
supernat
hybridoma
cell
clone
tabl
littl
hi
activ
detect
concentr
purifi
data
shown
base
result
western
blot
analysi
humab
seem
recogn
sequenti
epitop
ha
use
seri
overlap
peptid
cover
entir
sequenc
region
tri
identifi
neutral
epitop
interestingli
mab
show
respons
synthes
peptid
ie
signific
respons
region
aa
aa
peptid
span
overlap
region
aa
respect
fig
region
highli
conserv
except
aa
amino
acid
locat
underneath
receptorbind
site
ha
globular
region
fig
sequenc
analysi
v
h
v
l
region
humab
perform
amino
acid
sequenc
complementaritydetermin
region
cdr
deduc
compar
fig
although
recogn
region
humab
differ
amino
acid
residu
cdr
two
serotyp
influenza
viru
influenza
influenza
b
virus
circul
predominantli
serotyp
b
virus
highli
prevail
last
year
japan
fact
humab
obtain
five
japanes
volunt
given
vaccin
mostli
recogn
b
virus
humab
broadli
reactiv
past
strain
b
virus
reveal
pap
stain
well
vn
assay
nine
humab
obtain
studi
show
crossreact
widerang
past
strain
influenza
b
viru
addit
crossreact
also
observ
vn
test
result
may
suggest
sinc
human
histori
exposur
influenza
viru
antigen
natur
infect
well
influenza
vaccin
immun
cell
recogn
global
epitop
influenza
viru
seem
quickli
respond
vaccin
therefor
use
pbmc
week
postvaccin
cell
fusion
may
advantag
prepar
widerang
subtypereact
mab
like
humab
recogn
two
separ
region
aa
aa
locat
close
three
dimension
structur
novel
human
epitop
result
suggest
recogn
conform
epitop
sever
studi
ha
epitop
influenza
use
murin
mab
rabbit
human
polyclon
antisera
moreov
mous
mab
recogn
conform
epitop
contain
aa
report
howev
epitop
overlap
aa
epitop
noteworthi
mention
two
humab
recogn
epitop
highli
conserv
sequenc
independ
prepar
two
volunt
confirm
differ
sequenc
cdr
conclus
develop
humab
use
pbmc
volunt
natur
expos
influenza
virus
vaccin
well
patient
influenza
infect
convalesc
phase
would
provid
potenti
therapeut
applic
c
